Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 11/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14979246 | 0.88 | TSHR (0.54) | MAP2K4MAPK1MAPK6LMNATSHR | |
| SCHEMBL30965223 | 0.88 | TSHR (0.54) | MAP2K4MAPK1MAPK6LMNATSHR | |
| SCHEMBL14564411 | 0.81 | MAPT (0.49) | MAP2K4MAPK1MAPK6LMNAMAP2K7 | |
| SCHEMBL6612568 | 0.81 | GSK3B (0.56) | MAP2K4MAPK1LMNAPTGS2GSK3B | |
| SCHEMBL28776089 | 0.81 | PDPK1 (0.51) | LMNAGSK3BABL1BCR | |
| SCHEMBL14979217 | 0.80 | SMN1; SMN2 (0.55) | MAP2K4MAPK1MAPK6LMNAGSK3B | |
| SCHEMBL5953156 | 0.80 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6MAP2K7ITK | |
| SCHEMBL462088 | 0.77 | LMNA (0.68) | MAP2K4MAPK1MAPK6LMNA | |
| SCHEMBL29651055 | 0.77 | LMNA (0.68) | MAP2K4MAPK1MAPK6LMNA | |
| SCHEMBL19570332 | 0.77 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6MAP2K7ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408064-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | GENETOLEAD INC. (CA) | 2024-12-12 | — | — | US | disclosed |
| EP-2781508-B9 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2781508-B9 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2781508-B1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2018-12-12 | — | — | EP | disclosed |
| US-9725442-B2 | Heterocyclic derivative having PGD2 receptor antagonist activity | SHIONOGI & CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| EP-2752410-B1 | HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | SHIONOGI & CO (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-9233098-B2 | Nitrogen-containing fused ring compounds as CRTH2 antagonists | KBP BIOSCIENCES CO., LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233098-B2 | Nitrogen-containing fused ring compounds as CRTH2 antagonists | KBP BIOSCIENCES CO., LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| CN-105073741-A | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL MYERS SQUIBB CO | 2015-11-18 | — | — | CN | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| EP-2781508-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP Biosciences Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| EP-2781508-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP Biosciences Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-18 | — | — | US | disclosed |
| EP-2752410-A1 | HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | Shionogi & Co., Ltd. (JP) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013071880-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | 山东亨利医药科技有限责任公司 (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | PTGDR, PTGDR2, PTGER4 | MAP2K4 2710/4885MAPK1 1480/4885MAPK6 1527/4885 |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, NR3C2 | MAP2K4 1653/4885MAPK1 1852/4885MAPK6 2792/4885 |
| US-20240408064-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MAP2K4 666/4885MAPK1 85/4885MAPK6 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.